Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys New Stake in Amneal Pharmaceuticals, Inc. $AMRX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 41,980 shares of the company’s stock, valued at approximately $522,000.

A number of other large investors also recently modified their holdings of the business. Oliver Luxxe Assets LLC bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $1,972,000. Artemis Investment Management LLP bought a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $1,574,000. SG Americas Securities LLC raised its holdings in Amneal Pharmaceuticals by 2,866.0% during the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock worth $9,889,000 after purchasing an additional 758,343 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in Amneal Pharmaceuticals in the first quarter worth approximately $936,000. Finally, Assenagon Asset Management S.A. lifted its position in Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after purchasing an additional 1,611,698 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $17.85 on Friday. The company has a market capitalization of $5.69 billion, a PE ratio of 46.97 and a beta of 1.26. The stock has a fifty day moving average of $15.05 and a 200-day moving average of $13.89. Amneal Pharmaceuticals, Inc. has a one year low of $7.66 and a one year high of $18.39.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on AMRX shares. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group boosted their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 17.30% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.